Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Risk of recurrent H pylori infection after initial eradication

This  week's issue of the Journal of the American Medical Association investigates the risk of recurrent H pylori infection 1 year after initial eradication therapy in Latin American communities.

News image

The long-term effectiveness of Helicobacter pylori eradication programs for preventing gastric cancer will depend on recurrence risk and individual and community factors.

Dr Douglas Morgan and colleagues estimated the risk of H pylori recurrence and assess factors associated with successful eradication 1 year after treatment.

Cohort analysis of 1463 randomized trial participants aged 21 to 65 years from 7 Latin American communities, who were treated for H pylori and observed between 2009 and 2011.

Patients were randomized to 1 of 3 treatment groups, including 14-day lansoprazole, amoxicillin, and clarithromycin, 5-day lansoprazole and amoxicillin followed by 5-day lansoprazole, clarithromycin, and metronidazole, or 5-day lansoprazole, amoxicillin, clarithromycin, and metronidazole.

The research team reported that participants with a positive C-urea breath test (UBT) 6 to 8 weeks posttreatment were offered voluntary re-treatment with 14-day bismuth-based quadruple therapy.

One year after treatment for H pylori infection, recurrence occurred in 12%
Journal of the American Medical Association

Recurrent infection after a negative posttreatment urea breath test and factors associated with successful eradication at 1-year follow-up.

The doctors noted that among participants with urea breath test-negative results who had a 1-year follow-up urea breath test, 125 tested urea breath test positive, a recurrence risk of 12%.

Recurrence was significantly associated with study site, nonadherence to initial therapy, and children in the household.

The researchers found that of the 281 with positive posttreatment urea breath test results, 138 completed re-treatment, of whom 93 tested urea breath test negative at 1 year.

Among the 1340 who had a 1-year urea breath test, 80%, 79%, and 78% had urea breath test-negative results in the triple, sequential, and concomitant groups, respectively, with 79% overall effectiveness.

In a single-treatment course analysis that ignored the effects of re-treatment, the percentage of urea breath test-negative results at 1 year was and was significantly associated with study site, adherence to initial therapy, male sex, and age.

The team of doctors reported that one-year effectiveness among all 1463 enrolled participants, considering all missing urea breath test results as positive, was 73%.

Dr Morgan's team concluded, "One year after treatment for H pylori infection, recurrence occurred in 12% of participants who had negative posttreatment urea breath test results."

"Recurrence determinants may be as important as specific antibiotic regimen in determining the long-term success of H pylori eradication interventions."

"Study findings are relevant to the feasibility of programs for the primary prevention of gastric cancer in high-incidence regions of Latin America."

JAMA 2013; 309(6): 578-586
15 February 2013

Go to top of page Email this page Email this page to a colleague

 05 March 2015

Advanced search
 05 March 2015 
Neuroendocrine carcinoma of the colon and rectum
 05 March 2015 
Infliximab and immunosuppressant therapy in ulcerative colitis
 05 March 2015 
EPHXI polymorphism and esophageal cancer risk
 04 March 2015 
Management of IBD
 04 March 2015 
Multidisciplinary management of rectal cancer
 04 March 2015 
Progression of Barrett's
 03 March 2015 
EPHX1 polymorphism and esophageal cancer risk
 03 March 2015 
GI bleeding in chronic kidney disease patients on aspirin
 03 March 2015 
Risk of anastomotic leak after colectomy
 02 March 2015 
Genes and early diagnosis of IBD
 02 March 2015 
Assessment of GERD
 02 March 2015 
Liver disease in patients awaiting liver transplant
 27 February 2015 
Obesity and weight-loss therapy
 27 February 2015 
MRE performance in staging liver fibrosis
 27 February 2015 
Bleeding in diverticulosis
 26 February 2015 
Familial colorectal cancer risk and primary cancer
 26 February 2015 
Herbal products and the liver
 26 February 2015 
Questionnaires for GERD
 25 February 2015 
Exercise and NAFLD
 25 February 2015 
IBD in Korea
 25 February 2015 
Immunosuppressive therapy and T. whipplei
 24 February 2015 
Clinical trials in pediatric IBD
 24 February 2015 
Reducing health care costs in IBD
 24 February 2015 
GI bleeding after anticoagulation interruption
 23 February 2015 
Visceral abdominal obesity and IBS
 23 February 2015 
Crohn's outcomes with infliximab
 23 February 2015 
Intestinal microbiota and celiac disease
 20 February 2015 
H. pylori eradication
 20 February 2015 
Antiviral treatment and Hep C outcomes
 20 February 2015 
C. diff testing in IBD
 19 February 2015 
Peptic ulcer bleeding mortality in liver disease
 19 February 2015 
Intestinal microbiota in IBS
 19 February 2015 
Fecal microbial transplant in active Crohn's disease
 18 February 2015 
Genetic testing and GI cancers
 18 February 2015 
Placebo analgesia in functional abdominal pain
 18 February 2015 
Successful Hep C virus therapy
 17 February 2015 
Quality measures and colonoscopist selection
 17 February 2015 
Global incidence of esophageal cancer
 17 February 2015 
Anti-viral treatment and survival in Hep C
 16 February 2015 
Saliva for the diagnosis of GERD
 16 February 2015 
H pylori eradication therapy
 16 February 2015 
Medical marijuana for digestive disorders
 13 February 2015 
Beta-blockers in cirrhosis
 13 February 2015 
Liver disease and peptic ulcer bleeding
 13 February 2015 
Prevalence of microscopic colitis
 12 February 2015 
Liver disease in chronic Hep C
 12 February 2015 
Patient-reported outcomes in Hep C
 12 February 2015 
Patientsí colonoscopist selection
 11 February 2015 
Hepatic decompensation in Hep C cirrhosis
 11 February 2015 
Guidelines for the diagnosis of hepatocellular carcinoma
 11 February 2015 
NAFLD and CVD
 10 February 2015 
Percutaneous endoscopic gastrostomy
 10 February 2015 
Factors that influence hepatic steatosis
 10 February 2015 
Gene variants and Crohn's susceptibility
 09 February 2015 
Factors that influence gallstone surgery
 09 February 2015 
Factors associated with increased mortality in cirrhosis
 09 February 2015 
Use of immunomodulators in IBD
 06 February 2015 
Colorectal cancer risk in IBD
 06 February 2015 
H. pylori and peptic ulcer bleeding
 06 February 2015 
IBS and somatization

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us